We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BioMarin Pharmaceutical Inc | NASDAQ:BMRN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 82.44 | 80.56 | 88.10 | 0 | 09:10:31 |
Specifically, the BioMarin leadership team will highlight:
BioMarin speakers scheduled to present include:
Jean-Jacques Bienaimé, Chairman and Chief Executive OfficerHank Fuchs, M.D., Executive Vice President and Chief Medical OfficerWolfgang Dummer, M.D., Ph.D., Vice President, Clinical DevelopmentSarah Noonberg, M.D., Ph.D., Group Vice President, Head of Global Clinical DevelopmentLen Post, Ph.D., Group Vice President, Chief Scientific OfficerCamilla Simpson, M.Sc., Group Vice President, Regulatory Affairs
External key opinion leaders scheduled to present include:
Cary Harding, M.D., Professor of Molecular and Medical Genetics and Pediatrics at Oregon Health and Science University
John Pasi, Ph.D., Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London
Ravi Savarirayan, M.D., Professor, Department of Paediatrics, University of Melbourne
Live Video WebcastInterested parties may access a live video webcast that will include audio and slides of the presentations via the investor section of the BioMarin website, www.BMRN.com. A replay of the meeting will be archived on the site for at least one week.
For those who choose not to listen and view the event via webcast, dial-in information for the audio portion of the webcast can be accessed using:
U.S. / Canada Dial-in Number: (877) 303-6313 International Dial-in Number: (631) 813-4734 Conference ID: 93170415
About BioMarinBioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
1 Year BioMarin Pharmaceutical Chart |
1 Month BioMarin Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions